Company Filing History:
7 out of 432 
6 out of 272 
1 out of 45 
Years Active: 2013-2020
Title: **Yoshikane Kikushige: Innovator in Therapeutic Antibodies**
Introduction
Yoshikane Kikushige is a prominent inventor based in Fukuoka, Japan, known for his groundbreaking work in the field of therapeutic antibodies. With a total of seven patents to his name, Kikushige has made significant contributions to medical research, specifically targeting blood tumors.
Latest Patents
Among his latest inventions is the anti-TIM-3 antibody, which is designed to bind to the amino acid sequence of the extracellular region of the TIM-3 protein or its three-dimensional structure. This antibody exhibits high Antibody-Dependent Cellular Cytotoxicity (ADCC) activity. His patent also includes the hybridoma that produces this antibody, a DNA sequence encoding the antibody, and the vectors for its introduction into transformants. Furthermore, he has developed a therapeutic method for treating blood tumors by administering the TIM-3 antibody or its binding fragment to subjects displaying TIM-3 expression in specific cell fractions. This method holds promise for treating various blood-related diseases like Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and others.
Career Highlights
Kikushige has held significant positions at notable institutions, including Kyushu University National University Corporation and Kyowa Hakko Kirin Co., Limited. His work has been pivotal in understanding and addressing blood tumors, making him a respected name in the field of biomedical innovation.
Collaborations
Throughout his career, Kikushige has collaborated with esteemed colleagues such as Yoshimasa Inagaki and Koichi Akashi, contributing to his research and expanding the influence of his innovative work in therapeutic solutions.
Conclusion
Yoshikane Kikushige's innovations exemplify the potential of targeted therapies in combating complex diseases such as blood tumors. His patents and collaborative efforts continue to inspire advancements in medical research, positioning him as a leading figure in the development of antibody-based treatments.